This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
Bladder Cancer Weekly
May 18, 2026
Videos
Peer-to-Peer Clinical Conversations
AUA 2026 Preview: Perioperative EV/Pembro, ctDNA, and Bladder Preservation - Petros Grivas
Petros Grivas
Petros Grivas previews the AUA 2026 bladder cancer program.
View
AUA 2026 Bladder Cancer Program: Focus on BCG-Naive Intensification Trials - Bogdana Schmidt
Bogdana Schmidt previews the AUA 2026 bladder cancer program.
View
Beyond the Abstracts
Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract
Optimizing Oncological Outcomes in High-Grade Non-Muscle Invasive Bladder Cancer: The Impact of a Surgeon-Led Treatment Pathway - Beyond the Abstract
Conference Coverage
AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: Durvalumab with BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC
AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: A Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS, with or Without Papillary Disease: Pivotal Phase 2 Interim Results of Detalimogene Voraplasmid
AUA 2026: Immune Microenvironment Signatures of Response to Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
AUA 2026: Cost Effectiveness Analysis of Sasanlimab + BCG for High-Risk NMIBC: Analysis From CREST
AUA 2026: ADVANCED-2 (Cohort A): Interim 12-Month Efficacy and Safety Data in BCG-Naïve Participants with High-Grade Non-Muscle Invasive Bladder Cancer
Articles
Editor Selected Abstracts and Commentaries
Bladder Cancer
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment
Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.
Perioperative IMFINZI® (Durvalumab) plus Neoadjuvant EV Showed Statistically Significant and Clinically Meaningful Improvements in Event-Free Survival and Overall Survival in Muscle-Invasive Bladder Cancer in the Phase III VOLGA Trial
Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression.
Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial.
Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials
Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes.
Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy.
Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.
Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.
Real-World Effectiveness of Avelumab, Pembrolizumab, and Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma with Squamous Differentiation (ARON-2EV) - Beyond the Abstract
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
